Swedish Ibrance Registries Insights (SIRI)

Pfizer

Status: Active, not recruiting

Conditions: Malignant Neoplasm of Breast

Treatments: Drug: palbociclib

Study type: Observational

Funder types: Industry

Identifiers

NCT04654208

A5481158

SIRI (Other Identifier)

Details and patient eligibility

About

The main objectives of this study are to describe patient characteristics, treatment patterns and clinical outcomes of patients receiving palbociclib in Swedish clinical practice.

Enrollment: 1,500 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

1. One or more (≥1) filled prescription of palbociclib (ATC code: L01XE33)
2. Age ≥18 years at index date

Exclusion criteria

There are no exclusion criteria

Trial design

1,500 participants in 2 patient groups

HR+/HER2- locally advanced or MBC in combination with an aromatase inhibitor (AI)

Description:

Group Description: patients with at least one filled prescription of palbociclib (ATC (anatomic therapeutic chemical classification system ) code: L01XE33)

Treatment:

Drug: palbociclib

HR+/HER2- locally advanced or MBC cancer in combination with fulvestrant

Description:

Group Description: patients with at least one filled prescription of palbociclib ATC (code: L01XE33)

Treatment:

Drug: palbociclib